News | June 09, 2023
Cosette Pharmaceuticals acquires Intrarosa from Endoceutics
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
The product is expected to be launched in June 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
The company has reported total income of Rs. 815.11 crores during the period ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
